Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled nitric oxide versus sildenafil in newborns with congenital diaphragmatic hernia and pulmonary hypertension
2017-000421-13Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Jun 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in congenital diaphragmatic hernia (CDH) and pulmonary hypertension (PH) comparing Inhaled nitric oxide with Sildenafil (2 arms). Primary endpoint: Change in oxygenation index at 12 hours. Started Jun 2017; status: completed.
02
Drugs
nitric oxidesildenafil
03
Conditions
congenital diaphragmatic hernia (CDH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2017-000421-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000421-13.